Trial · NCT03085784
Intravitreal Aflibercept Injection for Radiation Retinopathy Trial
NCT03085784, Phase 2, Unknown, Amy C Schefler, MD
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Intravitreal Aflibercept Injection for Radiation Retinopathy Trial. Trials, record NCT03085784. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03085784
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intravitreal Aflibercept Injection for Radiation Retinopathy Trial
- NCT number
- NCT03085784
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Amy C Schefler, MD
- Conditions
- Radiation Retinopathy
- Interventions
- Aflibercept
- First posted
- 2017-03-21
- Last updated
- 2020-12-08
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety of intravitreal Aflibercept for the treatment of radiation retinopathy - Assessed by incidence of adverse events. | 52 Weeks | The primary objective of the study is to assess the safety of 2 mg intravitreal Aflibercept injections (IAI) for the treatment of radiation retinopathy including maculopathy and optic neuropathy. Assessed by incidence of adverse events. |
| Secondary | Resolution of macular edema (CRT) | 52 Weeks | Resolution of macular edema as measured by mean change in central retinal thickness |
| Secondary | Resolution of macular edema (% dry) | 52 Weeks | Resolution of macular edema as measured by % of patients who achieve a dry macula |
| Secondary | Stabilization and improvement in visual acuity | 52 Weeks | Stabilization and improvement in visual acuity as measured by the mean change in Early Treatment Diabetic Retinopathy Study best-corrected visual acuity |
| Secondary | Dosing frequency of intravitreal aflibercept injections | 52 Weeks | Dosing frequency of IAI as measured by number of injections |
| Secondary | Incidence of neovascularization, vitreous hemorrhage, and need for vitrectomy | 52 Weeks | Percentage of patients avoiding the development of increased neovascularization, vitreous hemorrhage, and need for vitrectomy |
| Secondary | Resolution of retinal hemorrhage, retinal exudates, optic disc edema, and capillary non-perfusion | 52 Weeks | Percentage of patients with resolution of retinal hemorrhages, retinal exudates, optic disc edema, capillary non-perfusion |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers12
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03085784
GET https://conductscience.org/api/trials/v1/NCT03085784/registered